Boehringer reports 6% sales growth for 2024

2 April 2025

Boehringer Ingelheim, now Germany's largest pharma company, today reported a currency-adjusted 6.1% gain in full-year 2024 revenues, buoyed by its diabetes and lung drugs.

Group sales reached 26.8 billion euros ($28.94 billion), the family-owned, unlisted drugmaker said in a statement. For 2025, Boehringer said it expects a slight increase in group revenues, adjusted for currency swings and one-off effects.

Human Pharma sales rose by 7.0% to 21.9 billion euros ($23.6 billion), led by Jardiance (empagliflozin) and Ofev (nintedanib). Sales of Jardiance, which is now also available for treatment of chronic kidney diseases, in addition to type 2 diabetes and heart failure, rose 14.6% to 8.4 billion euros. Ofev, which is used to treat idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases, grew 8.9% to 3.8 billion euros.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK